A newly developed medication for pulmonary hypertension targets blood vessels in the lungs, but does not affect blood vessels in the liver. Which of the following is most likely true of this medication?
A) It is a ligand that is specific for lung and liver blood-vessel receptors. but which is metabolized rapidly in the liver
B) It is a ligand that is specific for blood-vessel receptors in the lung but not in the liver
C) It is a receptor that is upregulated when oxygen tension in the lungs is low
D) It is a receptor that is only expressed on blood vessels in the lungs
Correct Answer:
Verified
Q10: What is the correct statement concerning noncompetitive
Q11: A patient comes to the ER having
Q12: Dose response data was collected during the
Q13: As a clinical consultant for the Breathright
Q14: Mutations in receptor tyrosine kinases would most
Q16: In which type of cell are ligand-gated
Q17: Which of the following is NOT true
Q18: Once phosphorylated, the intracellular segment of a
Q19: Isoproterenol produces maximal contraction of cardiac muscle
Q20: If 10 mg of naproxen produces the
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents